M Pharmaceutical Pilot Test Successfully Draws Blood Sample Using Wearable Monitoring System

M Pharmaceutical Inc. (CSE:MQ) reported that its human testing pilot demonstrated that a single-cell of its e-Mosquito prototype was able to penetrate the skin, reach a subcutaneous capillary and extract a blood sample for further in-situ glucose analysis.

As quoted in the press release:

“This is an exciting milestone in the development of the e-Mosquito technology and our electronically-controlled microsystem for minimally-invasive, periodic sampling of whole blood for the purpose of autonomous glucose monitoring in diabetics,” said Dr. Martin Mintchev, President & Chief Executive Officer of the Company.

“Simply put, we have demonstrated the practical feasibility of the e-Mosquito actuator, for which the Company has a pending patent,” explained Dr. Mintchev, who has based his long-standing research and biomedical technology development at the University of Calgary in Alberta.

The Company views the milestone as a big step forward in the development of a six-cell, autonomous e-Mosquito prototype and an integrated electronic glucose analysis system. It will now allow the Company to perform statistically sound, comprehensive, and comparative human testing in its quest to operationalize the e-Mosquito technology.

“We’re gratified by the results and look forward to taking the e-Mosquito technology to the level of pre-registration clinical trials,” said Dr. Mintchev.

The Company already has acquired or agreed to acquire two other biomedical technologies at the stage of pre-registration clinical trials, both of which are also designed to improve the lives of people dealing with obesity or diabetes: implantable gastric neurostimulators and ingestible pseudobezoars.

About the e-Mosquito:

The e-Mosquito is an integrated cuff-based blood glucose self-monitoring device invented at the University of Calgary by three M Diagnostics shareholders—Dr. Martin Mintchev, Dr. Orly Yadid-Pecht and Joseph Wang. By design, the device offers Type 2 diabetic patients and Type 1 insulin-dependent diabetics a more convenient, less invasive solution to blood glucose monitoring.

Click here to read the M Pharmaceutical Inc. (CSE:MQ) press release
Click here to see the M Pharmaceutical Inc. (CSE:MQ) profile.